<DOC>
	<DOCNO>NCT02321709</DOCNO>
	<brief_summary>Primary Objective : To assess tolerability safety SAR113244 male female lupus patient every 4 ( Q4 ) week repeat ascend subcutaneous dos SAR113244 . Secondary Objectives : To assess male female lupus patient : - The pharmacokinetics SAR113244 . - The pharmacodynamics SAR113244 follow disease-related parameter : - Safety Estrogens Lupus Erythematosus National Assessment - Systemic Lupus Erythematosus Disease Activity Index ( SELENA-SLEDAI ) score , British Isles Lupus Assessment Group ( BILAG ) score ( applicable ) , BILAG-Based Composite Lupus Assessment ( BICLA ) ( applicable ) , systemic lupus erythematosus responder index ( SRI ) ( applicable ) , Lupus-quality life ( QoL ) Functional Assessment Chronic Illness Therapy ( FACIT ) -Fatigue , anti-double strand deoxyribonucleic acid antibody ( anti-dsDNA Ab ) anti-nuclear antibody level ( ANA ) plasma complement level ( C3 , C4 ) , erythrocyte sedimentation ( SED ) rate C-reactive protein . - Peripheral blood B T cell subset .</brief_summary>
	<brief_title>Multiple Ascending Dose Study To Assess The Safety Profile Of SAR113244 Versus Placebo In Lupus Male And Female Patients</brief_title>
	<detailed_description>The total duration screen end study per subject 20 week post-study observation Day 226 anti-drug antibody assessment ( patient positive anti-drug antibody end study ) .</detailed_description>
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Inclusion criterion : Male female patient , 18 75 year age , inclusive . Clinical diagnosis systemic lupus erythematosus ( SLE ) American College Rheumatology criterion . Autoantibodyposititve . On active stable SLE disease . Exclusion criterion : Pregnant nursing . Have receive treatment investigational drug 4 month prior screen 5 halflives drug , whichever longer . Have receive intravenous oral cyclophosphamide within 180 day Day 0 . Severe active lupus nephritis chronic renal insufficiency . Active chronic , severe neuropsychiatric lupus . Acute , recent ( within 4 week screen ) , chronic frequently recur infection ( ) , except minor infection . Have current drug alcohol abuse dependence . Have historically positive test test postitive screening HIV , hepatitis B , hepatitis C. The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>